Meeting
2019 Gastrointestinal Cancers Symposium
CA19-9 decrease and overall survival according to platelet level in patients with metastatic pancreatic cancer.
Authors
Yang Chen
Chinese People's Liberation Army General Hospital, Beijing, China
Yang Chen , Guanghai Dai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Prevention, Diagnosis, and Screening
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 203)
DOI
10.1200/JCO.2019.37.4_suppl.203
Abstract #
203
Poster Bd #
A19
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Associations between BMI, morphomics and survival in 528 patients with metastatic pancreatic cancer.
First Author: Valerie Gunchick
Poster
2016 Gastrointestinal Cancers Symposium
Nutritional status and outcomes of older versus younger patients (pts) with metastatic pancreatic cancer (mPC).
First Author: Namrata Vijayvergia
Poster
2015 Gastrointestinal Cancers Symposium
Phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer: Clinical update on long term survival and biomarker correlates to overall survival.
First Author: Chan Whiting
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Kinetics of CA19-9 decline in a randomized phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracial/leucovorin (NALIRIFOX) or nab-paclitaxel plus gemcitabine (GEM+NABP) in patients who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas (NAPOLI 3).
First Author: Sreenivasa R Chandana